Eckert & Ziegler BEBIG: Year Results 2011, Third Year in a Row with a Net Profit
(Thomson Reuters ONE) -
Regulated information
Year Result 2011
Third Year in a Row with a Net Profit
March 30, 2012
Seneffe - Belgium, March 30, 2012, Eckert & Ziegler BEBIG (Euronext: EZBG;
Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its consolidated
results for the year ending December 31, 2011.
A summary report including the milestones of the year 2011 and a selection of
consolidated key figures for the 12 months ending December 31, 2011 can be
downloaded at:
http://www.bebig.eu/investor_relations/financial_reports/interim_results.html
Sales for the year 2011 reached 30.4 million EUR, compared to 32.4 million EUR
in 2010, showing a decrease of 6%. The main components were income generated by
the sales of permanent brachytherapy I-125 radiotherapeutic implants as well as
income from temporary brachytherapy equipment, i.e. HDR equipment using Co-60
(Cobalt 60) and Ir-192 (Iridium 192) sources (also called "afterloaders").
Beside the decrease of total sales, the stable recurring sales of goods and
services increased by 6%.
Operating result reached 5.1 million EUR for the whole year 2011, compared to
6.0 million EUR in 2010, showing a decrease of 14%. Earnings before interest and
taxes (EBIT) have reached 5 million EUR in 2011, versus 4.2 million EUR in
2010, showing an increase of 20.7%. It should be recalled that the EBIT result
of 2010 has suffered a major impairment loss of 1.4 million EUR on a loan
granted to Core Oncology Incorporation.
Cash amounted to 3.1 million EUR at the end of December 2011, versus 5.2 million
EUR in December 2010. The equity to assets ratio stood at 66.7% end of December
2011.
Shareholders Calendar:
Trading Update 1Q-2012: Thursday, May 3, 2012
Annual General Meeting: Monday, June 11, 2012 (10:30 am)
Half-Year Results 2012: Tuesday, August 14, 2012
Trading Update 3Q-2012: Tuesday, November 6, 2012
The above results and trading updates will be published before market opens on
the respective dates.
Eckert & Ziegler BEBIG
...Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group, active in the medical device
sector of the healthcare industry.
Its core business is the treatment of cancer by brachytherapy, a special form of
radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and
is headquartered in Belgium. It has a production facility in Germany and
subsidiaries throughout Europe, as well as in India. Eckert & Ziegler BEBIG has
also established a worldwide network of distributors and agents to support its
product line.
The company's products and equipment are intended for use by oncologists,
radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. It has been listed on the
Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR;
Bloomberg: EZBG: BB).
Contact:
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir(at)bebig.eu
www.bebig.eu
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
[HUG#1598525]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Tombstone Exploration Corporation's Additional Approved Permits Double the Size of Its 100% Owned Epithermal Disseminated Gold ProspectDatum: 30.03.2012 - 07:47 Uhr
Sprache: Deutsch
News-ID 130225
Anzahl Zeichen: 4001
contact information:
Town:
Seneffe
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 258 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Eckert & Ziegler BEBIG: Year Results 2011, Third Year in a Row with a Net Profit"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert & Ziegler BEBIG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
